Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome

Show simple item record

dc.contributor.author Lahtinen, Perttu
dc.contributor.author Jalanka, Jonna
dc.contributor.author Hartikainen, Anna
dc.contributor.author Mattila, Eero
dc.contributor.author Hillilä, Markku
dc.contributor.author Punkkinen, Jari
dc.contributor.author Koskenpato, Jari
dc.contributor.author Anttila, Veli-Jukka
dc.contributor.author Tillonen, Jyrki
dc.contributor.author Satokari, Reetta
dc.contributor.author Arkkila, Perttu
dc.date.accessioned 2021-04-27T21:49:16Z
dc.date.available 2021-12-18T03:45:19Z
dc.date.issued 2020-06
dc.identifier.citation Lahtinen , P , Jalanka , J , Hartikainen , A , Mattila , E , Hillilä , M , Punkkinen , J , Koskenpato , J , Anttila , V-J , Tillonen , J , Satokari , R & Arkkila , P 2020 , ' Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome ' , Alimentary Pharmacology & Therapeutics , vol. 51 , no. 12 , pp. 1321-1331 . https://doi.org/10.1111/apt.15740
dc.identifier.other PURE: 136259111
dc.identifier.other PURE UUID: 6e5e8f1b-cec6-40af-9dc2-c6f3e82d9a01
dc.identifier.other RIS: urn:24D705B1AF54BA5140F61A9D4ABB1427
dc.identifier.other WOS: 000528922700001
dc.identifier.other ORCID: /0000-0002-3847-8136/work/76330213
dc.identifier.uri http://hdl.handle.net/10138/329448
dc.description.abstract Summary Background Irritable bowel syndrome (IBS) has been associated with microbial dysbiosis. Aim To investigate the efficacy of faecal microbiota transplantation (FMT) in the treatment of IBS. Methods Forty-nine IBS patients were randomised to receive autologous or allogenic FMT via colonoscopy. The primary endpoint was a sustained, minimum of 50-point, reduction in the IBS Symptom Severity Score. The secondary outcomes were levels of anxiety and depression, changes in quality of life, gut microbiota and faecal water content as assessed with validated questionnaires, intestinal microbiota composition and stool dry weight. Results The primary endpoint was not achieved in either group. However, there was a transient reduction in the mean IBS Symptom Severity Score in the FMT group at 12 weeks after treatment as compared to baseline (P = 0.01). The groups did not differ in the number of patients achieving clinical response at 12 weeks. In the FMT-treated patients, microbial composition had changed to resemble that of the donor and the stool water content decreased significantly compared to baseline. The depression score decreased in patients with a reduction in IBS symptoms after FMT, but not in those placebo-treated patients who experienced a reduction in IBS symptoms. Conclusions FMT provided only a transient relief of symptoms, although it induced a sustained alteration in the microbiota of IBS patients. Therefore, FMT delivered by a single infusion via colonoscopy cannot be recommended as a treatment for IBS in clinical practice. ClinicalTrials.Org, Trial registration number: NCT03561519. en
dc.format.extent 11
dc.language.iso eng
dc.relation.ispartof Alimentary Pharmacology & Therapeutics
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 3111 Biomedicine
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.subject RECURRENT
dc.subject EFFICACY
dc.subject VALIDATION
dc.subject REMISSION
dc.subject BACTERIAL
dc.subject SEVERITY
dc.subject SYMPTOMS
dc.subject ANXIETY
dc.subject IBS
dc.subject 317 Pharmacy
dc.title Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome en
dc.type Article
dc.contributor.organization Päijät-Häme Welfare Consortium
dc.contributor.organization HYKS erva
dc.contributor.organization Faculty of Medicine
dc.contributor.organization University of Helsinki
dc.contributor.organization HUMI - Human Microbiome Research
dc.contributor.organization Research Programs Unit
dc.contributor.organization HUS Internal Medicine and Rehabilitation
dc.contributor.organization Infektiosairauksien yksikkö
dc.contributor.organization Department of Medicine
dc.contributor.organization Helsinki University Hospital Area
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization Gastroenterologian yksikkö
dc.contributor.organization Clinicum
dc.contributor.organization HUS Inflammation Center
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1111/apt.15740
dc.relation.issn 0269-2813
dc.rights.accesslevel openAccess
dc.type.version acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Randomised_clinical_trial_AAM.pdf 119.0Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record